Stuart A. Aaronson

Biochemistry, Genetics and Molecular Biology · Life Sciences

116h-index63.2kcitations628works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(156), Animal Virus Infections Studies(77), Cancer-related Molecular Pathways(76), Viral Infectious Diseases and Gene Expression in Insects(51), RNA Interference and Gene Delivery(43)

Publications628 total

Figure S3 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Figure S1 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Data from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Figure S4 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Figure S2 from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Supplementary Data Legends from RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
2026Open Access
Lost in Translation: Policymakers are not really listening to Citizen Concerns about AI
arXiv (Cornell University)·2025Open Access
Retraction Note: ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation
Nature Communications·2025Open Access
RAS Mutation–Specific Responses to Paralog- and State-Selective RAS Inhibitors
Molecular Cancer Research·2025· 1 citedOpen Access
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Nature Communications·2025· 1 citedOpen Access
Abstract LB424: Mechanistic rationale for combination of RAF/MEK glue avutometinib with a pan-RAF inhibitor for RAS-mutant tumor-selective therapy
Cancer Research·2025
Abstract LB294: Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitor
Cancer Research·2025
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors
2025· 2 citedOpen Access
Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4
The EMBO Journal·2025· 2 citedOpen Access
AI and trade: The WTO's thoughtful but incomplete assessment
Econstor (Econstor)·2025Open Access
Public concerns about AI: Are getting lost in translation
Econstor (Econstor)·2025Open Access
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
2023Open Access
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Cell Death and Differentiation·2023· 326 citedOpen Access
Fig S1 from World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates
2023Open Access
Fig S5 from World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates
2023Open Access
page 1 of 32Next →

Frequent Co-authors

George J. Todaro(5), Jeffrey S. Rubin(5), Jacalyn H. Pierce(5), Paul W. Finch(5), Anna Bafico(5), Ilio Vitale(4), John Abrams(4), Emad S. Alnemri(4), David W. Andrews(4), Eric H. Baehrecke(4), Nicolás G. Bazán(4), Mikhail V. Blagosklonny(4), Klas Blomgren(4), Christoph Borner(4), Catherine Brenner(4), John A. Cidlowski(4), Aaron Ciechanover(4), Ruggero De Maria(4), Brian David Dynlacht(4), Wafik S. El‐Deiry(4)